Abstract
A problem usually not taken into account when a quantitative HPLC method for phenylbutazone is developed is the degradation of this drug and its metabolites not only upon storage, but also on extraction under acidic conditions, especially when the temperature is raised. Moreover, the degradation products in the chromatograms may interfere with the determination of gammahydroxyphenylbutazone. In our newly developed HPLC method, using feprazone as an internal standard, extreme care is taken to avoid degradation of the compounds during the extraction procedure. In view of the present results it is concluded that previously published data on phenylbutazone, oxyphenbutazone and gammahydroxyphenylbutazone levels should be considered with reserve.
Similar content being viewed by others
References
Inham WH. Study of fatal bone marrow depression with special reference to phenylbutazone and oxyphenbutazone. Br Med J 1977;1:1500–5.
Burns JJ, Rose RK, Chenkin T, Goldman A, Schülert A, Brodie BB. The physiological disposition of phenylbutazone (Butazolidine®) in man and a method for its estimation in biological material. J Pharmacol Exp Ther 1953;109:346–57.
Burns JJ, Rose RK, Goodwin S, Reickenthal J, Horning EC, Brodie BB. The metabolic fate of phenylbutazone in man. J Pharmacol Exp Ther 1955;113:481–9.
Wallace JE. Ultraviolet spectrophotometric determination of phenylbutazone in biologic specimens. J Pharm Sci 1968;57:2053–6.
Perego R, Martinelli E, Vanoni PC. Gas chromatographic assay of phenylbutazone in biological fluids. J Chromatogr 1971;54:280–1.
McGilveray IJ, Midha KK, Brien R, Wilson R. The assay of phenylbutazone in human plasma by specific and sensitive gas-liquid chromatographic procedure. J Chromatogr 1974;89:17–22.
Bruce RB, Maynard WR, Dunning LK. Oxyphenbutazone and phenylbutazone determination in plasma and urine by GLC. J Pharm Sci 1974;63:446–8.
Midha KK, McGilveray IJ, Charette C. GLC determination of plasma concentration of phenylbutazorle and its metabolite oxyphenbutazone. J Pharm Sci 1974;63:1234–9.
Midha KK, McGilveray IJ, Charette C. GLC determination of gammahydroxyphenylbutazone in plasma. J Pharm Sci 1974;63:1751–4.
Sioufi A, Candal F, Marfil F. GLC determination of phenylbutazone in human plasma. J Pharm Sci 1978;67:243–5.
Budd RD. Gas chromatographic determination of phenylbutazone in biological fluids. J Chromatogr 1982;243:368–71.
Pound NJ, McGilveray IJ, Sears RW. Analysis of phenylbutazone in plasma by high-speed liquid chromatograpy. J Chromatogr 1974;89:23–30.
Pound NJ, Sears RW. Simultaneous determination of phenylbutazone and oxyphenbutazone in plasma by high-speed liquid chromatography. J Pharm Sci 1975;64:284–7.
Alvinerie M. Reversed phase high-performance liquid chromatography of phenylbutazone in body fluids. J Chromatogr 1980;181:132–4.
Aarons L, Higham C. An improved HPLC assay for monitoring phenylbutazone and its two major oxidised metabolites in plasma. Clin Chim Acta 1980;105:377–82.
Marunaka T, Shibata T, Minami Y, Umeno Y. Simultaneous determination of phenylbutazone and its metabolites in plasma and urine by high-performance liquid chromatography. J Chromatogr 1980;183:331–8.
Bellward GD, Morgan RG, Beauline VH, Mitchell AG. Effect of phenylbutazone breakdown produced on drug metabolism assay. J Pharm Pharmacol 1972;24:338–9.
Awang DVC, Vincent A, Matsui F. Pattern of phenylbutazone degradation. J Pharm Sci 1973;62:1673–6.
Matsui F, Robertson DL, Poirier MA, Lovering EG. Identification of degradation products in a phenylbutazone tablet formulation. J Pharm Sci 1980;69:469–71.
Fabre H, Mandron B, Eddine H. Quality control of phenylbutazone. II: analysis of phenylbutazone and its decomposition products in drugs by high-pressure liquid chromatography. J Pharm Sci 1982;71:120–2.
Aarbakke J, Bakke OM, Milde ET, Davies DS. Disposition and oxidative metabolism of phenylbutazone in man. Eur J Clin Pharmacol 1977;11:359–66.
Dieterle W, Faigle JW, Früh F, et al. Metabolism of phenylbutazone in man. Drug Res 1976;26:572–7.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Franssen, M.J.A.M., Tan, Y., Freij, I. et al. Specimen handling in an HPLC determination of phenylbutazone and its major metabolites in plasma, avoiding degradation of the compounds. Pharmaceutisch Weekblad Scientific Edition 8, 229–233 (1986). https://doi.org/10.1007/BF01957783
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF01957783